Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 388

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2

Open access
Lipton, Richard B., Goadsby, Peter J., Smith, Jeff, Schaeffler, Barbara A., Biondi, David M., Hirman, Joe, Pederson, Susan, Allan, Brent, Cady, Roger · 2020 · Neurology

Abstract

OBJECTIVE: To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of chronic migraine (CM). METHODS: The Prevention of Migraine via Intravenous ALD403 Safety and Efficacy-2 (PROMISE-2) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with CM were randomly assigned to receive IV eptinezumab 100 mg, eptinezumab 300 mg, or placebo administered on day 0 and week 12. The primary endpoint was change from baseline in mean monthly migraine days (MMDs) over weeks 1 to 12. RESULTS: < 0.0001 vs placebo). Treatment-emergent adverse events (TEAEs) were reported by 43.5% (100 mg), 52.0% (300 mg), and 46.7% (placebo) of patients. Nasopharyngitis was the only TEAE reported for >2% of eptinezumab-treated patients at an incidence of >2% over placebo; it occurred in the 300 mg eptinezumab arm (eptinezumab 9.4%, placebo 6.0%). CONCLUSION: In patients with CM, eptinezumab 100 and 300 mg was associated with a significant reduction in MMDs from the day after IV administration through week 12, was well tolerated, and demonstrated an acceptable safety profile. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with CM, a single dose of eptinezumab reduces MMDs over 12 weeks of treatment. CLINICALTRIALSGOV IDENTIFIER: NCT02974153.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000009169

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 388

Metadata

Authors
Lipton, R. B., Goadsby, P. J., Smith, J., Schaeffler, B. A., Biondi, D. M., Hirman, J., Pederson, S., Allan, B., & Cady, R.
Venue
Neurology
Published
2020-03-31
Volume
94
Issue
13
Pages
e1365-e1377
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W3013502865
Cited by
388
References
25
FWCI
39.89
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. https://app.cochat.ai/papers/10.1212/wnl.0000000000009169
The paper
Lipton, R. B., Goadsby, P. J., Smith, J., Schaeffler, B. A., Biondi, D. M., Hirman, J., Pederson, S., Allan, B., & Cady, R. (2020). Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. https://doi.org/10.1212/wnl.0000000000009169

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.